Director at 22nd Century is Selling Shares

By George MacDonald

Today, director at 22nd Century, Joseph Pandolfino, sold stocks of XXII for $86.48k.

Based on 22nd Century`s latest earnings report from March 31, the company posted quarterly revenue of $616.1k and GAAP net loss of $4.12M. In comparison, last year the company earned revenue of $16.11k and had a GAAP net loss of $1.97M. The company has a one year high of $3.56 and a one year low of $0.65. Currently, 22nd Century has an average volume of 240k.

Looking at blogger coverage of XXII, there is a 100% Bullish tendency on the stock, in relation to a 67% average bullish tendency within the Healthcare sector.

22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding.